share_log

AlloVir Analyst Ratings

Benzinga ·  Aug 18, 2023 18:56
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/18/2023 588.26% B of A Securities → $17 Initiates Coverage On → Buy
08/07/2023 709.72% Morgan Stanley $20 → $20 Reiterates Overweight → Overweight
04/26/2023 669.23% SVB Securities $16 → $19 Maintains Outperform
01/27/2023 709.72% Morgan Stanley $27 → $20 Maintains Overweight
01/23/2023 669.23% SVB Leerink $25 → $19 Maintains Outperform
11/07/2022 912.15% SVB Leerink $24 → $25 Maintains Outperform
09/09/2022 993.12% Morgan Stanley $32 → $27 Maintains Overweight
07/28/2022 831.17% SVB Leerink $30 → $23 Maintains Outperform
05/19/2022 1276.52% Piper Sandler $55 → $34 Maintains Overweight
02/10/2022 1114.57% SVB Leerink $32 → $30 Maintains Outperform
01/18/2022 1721.86% Morgan Stanley $48 → $45 Maintains Overweight
12/17/2021 1195.55% SVB Leerink $37 → $32 Maintains Outperform
11/08/2021 1397.98% SVB Leerink $41 → $37 Maintains Outperform
10/12/2021 1843.32% Morgan Stanley $47 → $48 Maintains Overweight
09/29/2021 9009.31% Morgan Stanley $175 → $225 Maintains Overweight
08/18/2021 1802.83% Morgan Stanley $50 → $47 Maintains Overweight
05/06/2021 1600.4% SVB Leerink $41 → $42 Maintains Outperform
04/19/2021 1924.29% Morgan Stanley $49 → $50 Maintains Overweight
08/24/2020 1924.29% JP Morgan → $50 Initiates Coverage On → Overweight
08/24/2020 1883.81% Morgan Stanley → $49 Initiates Coverage On → Overweight
08/24/2020 1559.92% SVB Leerink → $41 Initiates Coverage On → Outperform

What is the target price for AlloVir (ALVR)?

The latest price target for AlloVir (NASDAQ: ALVR) was reported by B of A Securities on August 18, 2023. The analyst firm set a price target for $17.00 expecting ALVR to rise to within 12 months (a possible 588.26% upside). 7 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for AlloVir (ALVR)?

The latest analyst rating for AlloVir (NASDAQ: ALVR) was provided by B of A Securities, and AlloVir initiated their buy rating.

When is the next analyst rating going to be posted or updated for AlloVir (ALVR)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AlloVir, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AlloVir was filed on August 18, 2023 so you should expect the next rating to be made available sometime around August 18, 2024.

Is the Analyst Rating AlloVir (ALVR) correct?

While ratings are subjective and will change, the latest AlloVir (ALVR) rating was a initiated with a price target of $0.00 to $17.00. The current price AlloVir (ALVR) is trading at is $2.47, which is within the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment